BRIEF-AstraZeneca Says Enhertu Granted Priority Review In US For Patients With HER2-Low Metastatic Breast Cancer

Reuters | Updated: 25-07-2022 11:59 IST | Created: 25-07-2022 11:50 IST
BRIEF-AstraZeneca Says Enhertu Granted Priority Review In US For Patients With HER2-Low Metastatic Breast Cancer
AstraZeneca logo Image Credit: ANI

AstraZeneca PLC:

* ASTRAZENECA PLC - ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC

* ASTRAZENECA - ENHERTU GRANTED PRIORITY REVIEW IN US FOR PATIENTS WITH HER2-LOW METASTATIC BREAST CANCER Source text for Eikon: Further company coverage:

TRENDING

1
ROI-The energy transition is starting to feed itself: Maguire

ROI-The energy transition is starting to feed itself: Maguire

Global
2
Georgia block party shooting kills two, injures dozens

Georgia block party shooting kills two, injures dozens

Global
3
Brazil's Flavio Bolsonaro beats polls in presidential vote, faces Lula in runoff

Brazil's Flavio Bolsonaro beats polls in presidential vote, faces Lula in ru...

Global
4
Paraguay opposition candidate wins Asuncion mayor's race in gauge of 2028 vote

Paraguay opposition candidate wins Asuncion mayor's race in gauge of 2028 vo...

Global

PERSPECTIVES AND INSIGHTS

Climate Tariffs Could Reshape Who Wins and Loses Across Global Value Chains

The Skills Gap Is Only Half the Story: Why Graduate Employability Can Erode After University

Why Energy Costs Hit Household Credit Harder Than Commercial Loans

Drone Images and AI Models Identify Key Rice Growth Stages with 91.7% Accuracy

DevShots

Latest News

Connect us on

LinkedIn Quora Youtube RSS
Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.

Subscribe to our Newsletter  

STANDARDS & POLICIES

EDITIONS

OTHER LINKS

CONNECT

Devdiscourse
Disclaimer | Terms of use | Privacy Policy

© Copyright 2026